Indometacin farnesil

Indometacin farnesil
Systematic (IUPAC) name
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Metabolism To indometacin
Biological half-life 1.5 hours
Excretion Renal
Identifiers
CAS Number 85801-02-1 YesY
ATC code None
PubChem CID 5282183
ChemSpider 4445378 YesY
Chemical data
Formula C34H40ClNO4
Molar mass 562.14 g/mol
  (verify)

Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.

External links

This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.